Liquid Cartilage and ChondroFiller are the same treatment

If you have come across both 'Liquid Cartilage™' and 'ChondroFiller®' during your research and wondered whether they are different products, the short answer is that they are not. ChondroFiller® liquid is the product name — an injectable collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany and CE-marked as a Class III medical device. Liquid Cartilage™ is the clinical procedure brand used by London Cartilage Clinic to describe the treatment pathway that uses ChondroFiller® as its implant. The two names point to the same thing.

The distinction matters mainly because patients tend to find the Liquid Cartilage name on clinic pages and ChondroFiller in peer-reviewed literature or manufacturer documentation. Both refer to the same injectable scaffold.

It is also worth noting that ChondroFiller® is not a hyaluronic acid viscosupplement or a standard gel injection. Its regulatory classification, composition, and intended mechanism are entirely different from those products — a distinction that becomes relevant when comparing treatment options.

How the collagen gel sets inside the joint

The product arrives in a ready-to-use two-chamber syringe containing ultrapure native Type I collagen in one chamber and a neutralising solution in the other. When the two are pressed through a mixing adapter during administration, they combine and — once placed within the cartilage defect — set into a dimensionally stable three-dimensional hydrogel in roughly three to five minutes. Think of it as a biological putty that conforms to the shape of the defect and holds its form without any additional fixative: no fibrin glue is required to keep it in place.

The scaffold itself contains no donor cells — it is entirely acellular. What it provides is a structured matrix that acts as a chemotactic signal, drawing the patient's own progenitor cells from the surrounding synovium and subchondral bone into the defect site. Those recruited cells gradually differentiate into chondrocytes — the specialised cells responsible for cartilage maintenance — while the collagen scaffold slowly resorbs. This process is described clinically as acellular matrix-induced chondrogenesis: the implant does not itself regrow cartilage, but supports the body's own repair processes by giving migrating cells an organised structure to populate and build within.

At London Cartilage Clinic, the scaffold is placed under ultrasound guidance as an outpatient injection. The image-guided approach allows precise delivery to the defect without theatre admission or surgical incisions.

Which patients and defects are suitable

Suitable candidates share a fairly specific profile: a focal, full-thickness cartilage defect — typically no larger than 3 cm² — in a synovial joint. The knee is the most commonly treated site, but the same indication applies to the hip, ankle, shoulder, elbow, wrist, and smaller joints. Patients tend to be at an earlier stage of joint deterioration, where the damage is localised rather than widespread across the joint surface.

Who is not suitable is equally important to state plainly. ChondroFiller is not appropriate for widespread or advanced osteoarthritis. In the Mazek 2021 hip cohort — a prospective study of 26 patients — those with pre-existing Tönnis grade 2–3 osteoarthritis had poor outcomes at three to five years, in contrast to the 81% good or excellent results seen in patients with focal lesions and healthier surrounding joint tissue. That finding reflects the biological reality: a scaffold requires viable surrounding cartilage and adequate cellular recruitment to support repair; it cannot reverse diffuse joint degeneration.

For patients who have been told they need surgery for a focal defect, it is worth knowing that ChondroFiller requires neither a cartilage biopsy nor bone microfracturing. It sits alongside procedures such as ACI, MACI, and osteochondral allograft as an alternative for suitable focal-defect candidates — not as a substitute for joint replacement in advanced disease.

Self-reported symptoms and even MRI findings are not sufficient to confirm suitability on their own. A formal clinical assessment, including imaging review and physical examination, is needed to establish whether the defect size, location, and surrounding joint condition make ChondroFiller the appropriate next step.

What the clinical results show

Across reported series, 70–85% of patients achieve meaningful symptom relief at three to five years — a figure that holds consistently across knee, hip, and smaller-joint applications.

In knee studies, the primary functional measure is the IKDC (International Knee Documentation Committee) score, a validated 0–100 scale where higher numbers reflect better knee function. The Jerosch et al. post-market clinical follow-up study found a mean improvement of 32.4 points sustained at three years, with patients reaching an average score of 80. The minimum clinically important difference on that scale is 16.7 points, meaning a 32-point improvement is roughly double the threshold at which patients are reliably expected to notice a functional change in daily life.

Structural repair is assessed on MRI using the MOCART score, which measures how completely repair tissue fills the defect and integrates with surrounding cartilage. European studies recorded MOCART scores of 81.6 to 84.3 at one year — up from 65.3 at four weeks — with a score above 80 taken to indicate more than 80% defect filling and sound tissue integration. The progressive rise from four weeks to twelve months reflects ongoing biological repair rather than a static structural result.

Hip outcomes from the Mazek 2021 cohort are covered in the preceding section and are not repeated here.

Safety data from reported adverse-event records show a complaint rate of approximately 0.06% — roughly one adverse event per 1,600 procedures — a figure that places the procedural risk profile in useful context for patients weighing their options.

The data above derive primarily from manufacturer-sponsored PMCF studies and single-centre cohorts; large independent randomised controlled trials have not been published. That distinction is worth holding alongside the results: the evidence establishes a credible and consistent signal, but independent confirmation at scale remains an outstanding gap.

Accessing ChondroFiller in the UK and what it costs

ChondroFiller is entirely self-funded private treatment in the UK. NHS commissioning does not cover it, and there is no blanket private medical insurance (PMI) approval — patients cannot assume their policy will pay.

Several UK insurers do recognise the relevant billing codes: W3111 (cartilage regeneration with collagen scaffold) and W8500. Bupa, Aviva, and WPA are the insurers most commonly cited for case-by-case approvals as at October 2025. The key word is case-by-case — each application is assessed on its clinical merits, and pre-authorisation in writing before the appointment is non-negotiable. Submitting for reimbursement after the procedure, without prior approval, is unlikely to succeed.

Guide costs at London Cartilage Clinic start from approximately £3,000 for a single-box ultrasound-guided injection. A dual-injection protocol combining ChondroFiller with Arthrosamid — used for more advanced presentations — carries a guide cost of approximately £6,000. The Tri-Active combination, which adds autologous mesenchymal stem cells to those two injections, is priced at approximately £11,000. These are guide figures confirmed by the treating clinic, not fixed prices; the exact cost depends on clinical requirements.

For the combination protocols, it matters that the injected products are doing different things. ChondroFiller is the regenerative scaffold component — an acellular matrix that recruits the body's own progenitor cells. Arthrosamid is a polyacrylamide hydrogel that works through a different, non-regenerative mechanism. Treating them as equivalent gel fillers would misrepresent both the science and the clinical rationale for combining them.

Getting an assessment at London Cartilage Clinic

The most useful thing to bring to a first appointment is any existing MRI of the affected joint. Defect size, depth, and the condition of the surrounding cartilage and bone are what a specialist needs to review first — scans from within the past 12 months are most informative, though older imaging still informs the discussion. Where no recent scan exists, one can be arranged as part of the assessment process. The consultation also covers clinical examination and a candid discussion of whether the defect profile, symptom pattern, and treatment goals align with what the injection pathway can realistically offer — arriving with a clear picture of how long symptoms have been present and which activities are most affected helps focus that conversation.

Professor Paul Y.F. Lee leads the ChondroFiller programme at London Cartilage Clinic, 66 Harley Street, as the clinician who introduced and performs the procedure in the UK. Patients can arrange an initial assessment through londoncartilage.com.